Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT07297875 für Achondroplasie ist noch nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia Phase 1, Phase 2 110 Randomisiert Dosis-Eskalation Offene Studie
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07297875 untersucht Behandlung im Zusammenhang mit Achondroplasie. Diese interventionsstudie der Phase 1 Phase 2 hat den Status noch nicht rekrutierend. Der Start ist für 10. Dezember 2025 geplant, bis 110 Teilnehmer aufgenommen werden. Durchgeführt von Abbisko Therapeutics Co, Ltd wird der Abschluss für 15. März 2031 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 22. Dezember 2025 aktualisiert.
Kurzbeschreibung
This is a multicenter, non-randomized, open-label, phase I/II study in children with ACH. This study will start with a dose escalation of ABSK061 in children with ACH to evaluate the safety, tolerability, PK, and efficacy. The RDE confirmation part will evaluate the safety and efficacy of ABSK061 at the recommended doses for expansion (RDEs) in children with ACH. All patients enrolled in the dose escalation part and ...Mehr anzeigen
Ausführliche Beschreibung
Up to 50 children aged 6 to < 12 years (inclusive of 6 years) with ACH and up to 30 children aged 3 to < 6 years (inclusive of 3 years) with ACH are expected to be enrolled in the dose escalation part of the study; up to 30 children aged 3 to < 12 years (inclusive of 3 years) with ACH are expected to be enrolled in the RDE confirmation part.
Children enrolled in this study will be required to complete at least 6 ...
Mehr anzeigenOffizieller Titel
A Phase Ⅰ/Ⅱ, Open-Label Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia
Erkrankungen
AchondroplasieWeitere Studien-IDs
- ABSK061-202
NCT-Nummer
Studienbeginn (tatsächlich)
2025-12-10
Zuletzt aktualisiert
2025-12-22
Studienende (vorauss.)
2031-03-15
Geplante Rekrutierung
110
Studientyp
Interventionsstudie
PHASE
Phase 1
Phase 2
Phase 2
Status
Noch nicht rekrutierend
Primäres Ziel
Behandlung
Zuteilungsmethode
Nicht zutreffend
Interventionsmodell
Einarmige Studie
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellABSK061 Dose escalation part will be divided into Part A and Part B according to patient age, with Part A enrolling children with ACH aged 6 to \< 12 years (inclusive of 6 years) and Part B enrolling children with ACH aged 3 to \< 6 years (inclusive of 3 years). In this study, two sentinel patients will be set for both parts of each dose level, thereby the interval for the first dose between the first 2 patients and the thir...Mehr anzeigen | ABSK061 ABSK061 is supplied as minitablets filled in capsules. Four strengths of capsules will be provided: 0.2 mg, 2 mg, 3 mg, and 5 mg. Each patient can only be administered with a single strength.
All patients will be administered orally once daily under the fasted state, i.e., fast from 2 hours before dosing to 1 hour after dosing. Dose will be calculated based on the patient's weight, and detailed rules for dose calcul...Mehr anzeigen |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Incidence of dose-limiting toxicities (DLTs) | Incidence of dose-limiting toxicities (DLTs) in the DLT observation period, defined as Day 1 to Day 28 of dosing | Day 1 to Day 28 of dosing |
Incidence and severity of adverse events (AEs) | Incidence and severity of adverse events (AEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) using Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0), and relatedness, rate of dose modifications (including dose interruption and dose reduction) or discontinuation of study drug due to toxicity, and changes from baseline in safety assessments such as laboratory parameters, x-ray, electrocardiograms (ECGs), echocardiograms, vital signs, and physical examinations (including ophthalmic examinations) | up to 87 weeks |
Changes from baseline in the Annualized Growth Velocity (AGV, cm/year) | Changes from baseline in the Annualized Growth Velocity (AGV, cm/year) over 52 weeks \[baseline is defined as the AGV obtained through at least 6 months of observation in the observational study (ABSK061-001)\] | Day 1 of dosing to 78-week End of Treatment |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Cmax | maximum observed concentration | Day 1 of dosing to 78-week End of Treatment |
Tmax | time to maximum observed concentration | Day 1 of dosing to 78-week End of Treatment |
AUC | area under the concentration-time curve | Day 1 of dosing to 78-week End of Treatment |
t1/2 | half-life | Day 1 of dosing to 78-week End of Treatment |
Vz/F | apparent volume of distribution | Day 1 of dosing to 78-week End of Treatment |
CL/F | apparent oral clearance | Day 1 of dosing to 78-week End of Treatment |
Cmax,ss | maximum observed concentration of steady/state | Day 1 of dosing to 78-week End of Treatment |
Cmin,ss | minimum observed concentration of steady/state | Day 1 of dosing to 78-week End of Treatment |
AUCtau,ss | area under the concentration-time curve after multiple dose | Day 1 of dosing to 78-week End of Treatment |
AR | accumulation ratio | Day 1 of dosing to 78-week End of Treatment |
standing height | calculated to the nearest 0.1 cm | Day 1 of dosing to 78-week End of Treatment |
sitting height | calculated to the nearest 0.1 cm | Day 1 of dosing to 78-week End of Treatment |
sitting height to standing height ratio | This parameter is calculated as the ratio of sitting height to total standing height. It is used to assess the abnormality in body proportions, specifically the relative trunk-to-lower limb length. In patients with achondroplasia, this ratio is typically increased. Within the clinical trial, this measure is used to evaluate the treatment drug's effect on body proportions. | Day 1 of dosing to 78-week End of Treatment |
height Z scores | This measure is defined as the number of standard deviation units by which the subject's height differs from the mean height of a healthy, age- and sex-matched reference population. It is a standardized value used to precisely quantify the degree of deviation from the normal growth curve. In the clinical trial, it serves as a key parameter for assessing the treatment's efficacy in improving linear height growth. | Day 1 of dosing to 78-week End of Treatment |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Kind
Mindestalter
3 Years
Zugelassene Geschlechter
Alle
Prior to screening, the guardians and children with ACH (if applicable) must voluntarily provide signed informed consent.
Patients with a clear clinical diagnosis of ACH confirmed by genetic testing for an FGFR3 mutation.
Male or female, age at screening:
Dose Escalation Part A: 6 to < 12 years (inclusive 6 years) Dose Escalation Part B: 3 to < 6 years (inclusive 3 years) RDE Confirmation Part: 3 to < 12 years (inclusive 3 years).
Have completed at least 6 months (i.e., the "Day 181" visit) of growth assessment and observation of natural history of ACH in the observational study (ABSK061-001) before study entry.
Tanner Stage 1 breast development for females or Tanner Stage 1 external genitalia development for males at screening
- Known allergy or hypersensitivity to any component of the study drug.
- Bone age ≥ 14 years as assessed by the investigator based on hand and wrist X-ray.
- Have a form of skeletal dysplasia other than ACH or known medical conditions that result in short stature or abnormal growth, including but not limited to severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Turner syndrome, pseudoachondroplasia, inflammatory bowel disease, chronic renal insufficiency, active celiac disease a, Vitamin D deficiency b, untreated hypothyroidism c, poorly controlled diabetes (HbA1c ≥8.0%) or diabetic complications
- History or presence of injury or disease of the growth plate(s), other than ACH, that affects growth potential of long bones.
- AGV ≤ 1.5 cm/year over at least 6 months (i.e., must have completed the 'Day 181' visit) in the observational study (ABSK061-001), or current evidence of growth plate closure (proximal tibia, distal femur).
- Current epiphyseal injury (Salter-Harris fracture) or severe hip pain.
- For ACH-related complications: current severe sleep apnea, symptomatic and/or requiring intervention for hydrocephalus, or spinal cord compression at the cranio-cervical junction, or prior ventriculoperitoneal shunt surgery.
- Have received any dose of medications affecting stature or body proportionality, such as human growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids within 12 months prior to screening.
- Prior treatment with any CNP analogues or FGFR inhibitors. Prior use of any investigational drugs or investigational medical devices that affect height or body proportion.
- History of any prior bone-related surgery that affects long bone growth, such as orthopaedic reconstructive surgery, limb lengthening, or osteotomy (patients who have previously undergone foramen magnum decompression or intervertebral disc/laminectomy are allowed if they have fully recovered after surgery and bone healing has occurred for at least 6 months. Patients who have previously undergone eight-plate epiphysiodesis are allowed if the plate has been removed and healed for at least 4 weeks).
Abbisko Therapeutics Co, LtdZentrale Studienkontakte
Kontakt: Jing Zhang, +86-15002126439, [email protected]
7 Studienstandorte in 1 Ländern
Beijing Municipality
Beijing Children's Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Di Wu, Kontakt, [email protected]
Di Wu, Hauptprüfer
Henan
Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, Henan, China
Hubei
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Yanqin Ying, Kontakt, [email protected]
Yanqin Ying, Hauptprüfer
Xiuhua Ren, Hauptprüfer
Shanghai Municipality
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Yongguo Yu, Kontakt, [email protected]
Yongguo Yu, Kontakt, [email protected]
Yongguo Yu, Hauptprüfer
Sichuan
Chengdu Women's and Children's Central Hospital, Chengde, Sichuan, China
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
Jin Wu, Kontakt, [email protected]
Jin Wu, Hauptprüfer
Zhejiang
Children's Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China